skin cancer
Dermtech Q3 Revenues Rise 122 Percent
The company said it recorded a 75 percent increase in billable sample volume during the quarter, and a 140 percent increase in assay revenues.
Castle Biosciences Q3 Revenues Rise 54 Percent
The company said it delivered 25 percent more DecisionDx-Melanoma test results year over year, and that the total number of all tests delivered rose 62 percent.
The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
Aug 9, 2021
Castle Biosciences Q2 Revenues Rise 79 Percent
May 11, 2021
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Mar 5, 2021
DermTech Q4 Revenues Up 31 Percent
Mar 9, 2020
Nov 11, 2019
Castle Biosciences Q3 2019 Revenues Quadruple
Sep 3, 2019
Castle Biosciences Q2 Revenues Up 168 Percent
Jul 25, 2019
Castle Bio Prices IPO at $16 per Share
Sep 26, 2018